Zacks Investment Research upgraded shares of Orgenesis (OTCMKTS:ORGS) from a sell rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD. “

Orgenesis stock opened at $4.32 on Wednesday. Orgenesis has a fifty-two week low of $3.78 and a fifty-two week high of $9.25. The firm has a fifty day moving average price of $4.28.

A number of institutional investors have recently bought and sold shares of ORGS. BlackRock Inc. lifted its position in shares of Orgenesis by 44.6% in the fourth quarter. BlackRock Inc. now owns 28,886 shares of the company’s stock valued at $135,000 after acquiring an additional 8,909 shares in the last quarter. Northern Trust Corp purchased a new stake in shares of Orgenesis in the fourth quarter valued at $70,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Orgenesis in the fourth quarter valued at $212,000.

Orgenesis Company Profile

Orgenesis Inc is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company’s subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products.

Further Reading: What is a stock split?

Get a free copy of the Zacks research report on Orgenesis (ORGS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.